167 related articles for article (PubMed ID: 8883623)
1. HIV protease inhibitors.
Carr A; Cooper DA
AIDS; 1996; 10 Suppl A():S151-7. PubMed ID: 8883623
[No Abstract] [Full Text] [Related]
2. [Resistance to protease inhibitors].
Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
[No Abstract] [Full Text] [Related]
3. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors.
Monod M; Borg-von Zepelin M; Telenti A; Sanglard D
Dermatology; 1999; 198(4):412-4. PubMed ID: 10490300
[No Abstract] [Full Text] [Related]
5. The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.
Karmochkine M; Si Mohamed A; Piketty C; Ginsburg C; Raguin G; Schneider-Fauveau V; Gutmann L; Kazatchkine MD; Belec L
Antiviral Res; 2000 Sep; 47(3):179-88. PubMed ID: 10974370
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Hoetelmans RM; Meenhorst PL; Mulder JW; Burger DM; Koks CH; Beijnen JH
Pharm World Sci; 1997 Aug; 19(4):159-75. PubMed ID: 9297727
[TBL] [Abstract][Full Text] [Related]
8. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
Inaba T; Fischer NE; Riddick DS; Stewart DJ; Hidaka T
Toxicol Lett; 1997 Dec; 93(2-3):215-9. PubMed ID: 9486958
[TBL] [Abstract][Full Text] [Related]
9. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.
Bektić J; Lell CP; Fuchs A; Stoiber H; Speth C; Lass-Flörl C; Borg-von Zepelin M; Dierich MP; Würzner R
FEMS Immunol Med Microbiol; 2001 Jul; 31(1):65-71. PubMed ID: 11476984
[TBL] [Abstract][Full Text] [Related]
10. Resistance to human immunodeficiency virus type 1 protease inhibitors.
Boden D; Markowitz M
Antimicrob Agents Chemother; 1998 Nov; 42(11):2775-83. PubMed ID: 9797203
[No Abstract] [Full Text] [Related]
11. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients.
Korting HC; Schaller M; Eder G; Hamm G; Böhmer U; Hube B
Antimicrob Agents Chemother; 1999 Aug; 43(8):2038-42. PubMed ID: 10428932
[TBL] [Abstract][Full Text] [Related]
12. Invirase resistance/cross-resistance data released.
AIDS Patient Care STDS; 1996 Jun; 10(3):185. PubMed ID: 11361626
[No Abstract] [Full Text] [Related]
13. HIV-1 protease inhibitors. A review for clinicians.
Deeks SG; Smith M; Holodniy M; Kahn JO
JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
[TBL] [Abstract][Full Text] [Related]
14. Antagonism of indinavir and saquinavir confirmed.
Bartnof HS
BETA; 1997 Sep; ():45. PubMed ID: 11364702
[TBL] [Abstract][Full Text] [Related]
15. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure.
Deeks SG; Grant RM; Beatty GW; Horton C; Detmer J; Eastman S
AIDS; 1998 Jul; 12(10):F97-102. PubMed ID: 9677159
[TBL] [Abstract][Full Text] [Related]
16. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
17. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors.
Descamps D; Apetrei C; Collin G; Damond F; Simon F; Brun-Vézinet F
AIDS; 1998 Jun; 12(9):1109-11. PubMed ID: 9662212
[No Abstract] [Full Text] [Related]
18. HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells.
Lucia MB; Rutella S; Leone G; Cauda R
AIDS; 2001 Nov; 15(17):2339-41. PubMed ID: 11698715
[No Abstract] [Full Text] [Related]
19. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
20. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
Eagling VA; Back DJ; Barry MG
Br J Clin Pharmacol; 1997 Aug; 44(2):190-4. PubMed ID: 9278209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
